Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): Stage 1 analysis of a randomised phase 3 study

Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul, Phillippe Solal-Céligny, Martin Barrett, Claude Berge, Beate Bittner, Axel Boehnke, Christine McIntyre, David MacDonald

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: Intravenous rituximab is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent rituximab serum concentrations might improve convenience and save health-care resources without sacrificing clinical activity. We aimed to assess pharmacokinetic non-inferiority of 3 week cycles of fixed-dose subcutaneous rituximab versus standard intravenous rituximab. Methods: In our two-stage, randomised, open-label, phase 3 trial, we enrolled patients with previously untreated grade 1-3a, CD20-positive follicular lymphoma at 67 centres in 23 countries. In stage 1, we randomly allocated patients 1:1 with the Pocock and Simon algorithm to intravenous rituximab (375 mg/m2) or fixed-dose subcutaneous rituximab (1400 mg), stratified by induction chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone or cyclophosphamide, vincristine, prednisone), Follicular Lymphoma International Prognostic Index score, and region. After randomisation, patients received one induction dose of intravenous rituximab in cycle 1 and then allocated treatment for cycles 2-8. Patients with a complete or partial response following induction therapy continued intravenous or subcutaneous rituximab as maintenance every 8 weeks. The primary endpoint was the ratio of observed rituximab serum trough concentrations (Ctrough) between groups at cycle 7 (before cycle 8 dosing) of induction treatment in a per-protocol population. Patients were analysed as treated for safety endpoints. Stage 2 follow-up is ongoing and is fully accrued. This study is registered with ClinicalTrials.gov, number NCT01200758. Findings: Between Feb 4, 2010, and Oct 21, 2011, we enrolled 127 patients. Pharmacokinetic data were available for 48 (75%) of 64 patients randomly allocated intravenous rituximab and 54 (86%) of 63 patients randomly allocated subcutaneous rituximab. Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab. 57 (88%) of 65 patients in the intravenous rituximab safety population had adverse events (30 [46%] grade ≥3), as did 57 (92%) of 62 patients in the subcutaneous rituximab safety population (29 [47%] grade ≥3). The most common grade 3 or worse adverse event in both groups was neutropenia (14 [22%] patients in the intravenous group and 16 [26%] patients in the subcutaneous group). Adverse events related to administration were mostly grade 1-2 and occurred in 21 (32%) patients in the intravenous group and 31 (50%) patients in the subcutaneous group. Interpretation: Stage 1 data show that the pharmacokinetic profile of subcutaneous rituximab was non-inferior to intravenous rituximab and was not associated with new safety concerns. Stage 2 will provide data for efficacy and safety of the subcutaneous administration. Funding: F Hoffmann-La Roche.

Original languageEnglish
Pages (from-to)343-352
Number of pages10
JournalThe Lancet Oncology
Volume15
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Follicular Lymphoma
Pharmacokinetics
Safety
Rituximab
Vincristine
Prednisone
Cyclophosphamide
Population
Induction Chemotherapy
Health Resources
Therapeutics
Random Allocation
Neutropenia
Serum

ASJC Scopus subject areas

  • Oncology

Cite this

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA) : Stage 1 analysis of a randomised phase 3 study. / Davies, Andrew; Merli, Francesco; Mihaljevic, Biljana; Siritanaratkul, Noppadol; Solal-Céligny, Phillippe; Barrett, Martin; Berge, Claude; Bittner, Beate; Boehnke, Axel; McIntyre, Christine; MacDonald, David.

In: The Lancet Oncology, Vol. 15, No. 3, 03.2014, p. 343-352.

Research output: Contribution to journalArticle

Davies, A, Merli, F, Mihaljevic, B, Siritanaratkul, N, Solal-Céligny, P, Barrett, M, Berge, C, Bittner, B, Boehnke, A, McIntyre, C & MacDonald, D 2014, 'Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): Stage 1 analysis of a randomised phase 3 study', The Lancet Oncology, vol. 15, no. 3, pp. 343-352. https://doi.org/10.1016/S1470-2045(14)70005-1
Davies, Andrew ; Merli, Francesco ; Mihaljevic, Biljana ; Siritanaratkul, Noppadol ; Solal-Céligny, Phillippe ; Barrett, Martin ; Berge, Claude ; Bittner, Beate ; Boehnke, Axel ; McIntyre, Christine ; MacDonald, David. / Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA) : Stage 1 analysis of a randomised phase 3 study. In: The Lancet Oncology. 2014 ; Vol. 15, No. 3. pp. 343-352.
@article{7cebfc8d4cf74c95aa7b97c9eadbffce,
title = "Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): Stage 1 analysis of a randomised phase 3 study",
abstract = "Background: Intravenous rituximab is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent rituximab serum concentrations might improve convenience and save health-care resources without sacrificing clinical activity. We aimed to assess pharmacokinetic non-inferiority of 3 week cycles of fixed-dose subcutaneous rituximab versus standard intravenous rituximab. Methods: In our two-stage, randomised, open-label, phase 3 trial, we enrolled patients with previously untreated grade 1-3a, CD20-positive follicular lymphoma at 67 centres in 23 countries. In stage 1, we randomly allocated patients 1:1 with the Pocock and Simon algorithm to intravenous rituximab (375 mg/m2) or fixed-dose subcutaneous rituximab (1400 mg), stratified by induction chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone or cyclophosphamide, vincristine, prednisone), Follicular Lymphoma International Prognostic Index score, and region. After randomisation, patients received one induction dose of intravenous rituximab in cycle 1 and then allocated treatment for cycles 2-8. Patients with a complete or partial response following induction therapy continued intravenous or subcutaneous rituximab as maintenance every 8 weeks. The primary endpoint was the ratio of observed rituximab serum trough concentrations (Ctrough) between groups at cycle 7 (before cycle 8 dosing) of induction treatment in a per-protocol population. Patients were analysed as treated for safety endpoints. Stage 2 follow-up is ongoing and is fully accrued. This study is registered with ClinicalTrials.gov, number NCT01200758. Findings: Between Feb 4, 2010, and Oct 21, 2011, we enrolled 127 patients. Pharmacokinetic data were available for 48 (75{\%}) of 64 patients randomly allocated intravenous rituximab and 54 (86{\%}) of 63 patients randomly allocated subcutaneous rituximab. Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90{\%} CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab. 57 (88{\%}) of 65 patients in the intravenous rituximab safety population had adverse events (30 [46{\%}] grade ≥3), as did 57 (92{\%}) of 62 patients in the subcutaneous rituximab safety population (29 [47{\%}] grade ≥3). The most common grade 3 or worse adverse event in both groups was neutropenia (14 [22{\%}] patients in the intravenous group and 16 [26{\%}] patients in the subcutaneous group). Adverse events related to administration were mostly grade 1-2 and occurred in 21 (32{\%}) patients in the intravenous group and 31 (50{\%}) patients in the subcutaneous group. Interpretation: Stage 1 data show that the pharmacokinetic profile of subcutaneous rituximab was non-inferior to intravenous rituximab and was not associated with new safety concerns. Stage 2 will provide data for efficacy and safety of the subcutaneous administration. Funding: F Hoffmann-La Roche.",
author = "Andrew Davies and Francesco Merli and Biljana Mihaljevic and Noppadol Siritanaratkul and Phillippe Solal-C{\'e}ligny and Martin Barrett and Claude Berge and Beate Bittner and Axel Boehnke and Christine McIntyre and David MacDonald",
year = "2014",
month = "3",
doi = "10.1016/S1470-2045(14)70005-1",
language = "English",
volume = "15",
pages = "343--352",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA)

T2 - Stage 1 analysis of a randomised phase 3 study

AU - Davies, Andrew

AU - Merli, Francesco

AU - Mihaljevic, Biljana

AU - Siritanaratkul, Noppadol

AU - Solal-Céligny, Phillippe

AU - Barrett, Martin

AU - Berge, Claude

AU - Bittner, Beate

AU - Boehnke, Axel

AU - McIntyre, Christine

AU - MacDonald, David

PY - 2014/3

Y1 - 2014/3

N2 - Background: Intravenous rituximab is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent rituximab serum concentrations might improve convenience and save health-care resources without sacrificing clinical activity. We aimed to assess pharmacokinetic non-inferiority of 3 week cycles of fixed-dose subcutaneous rituximab versus standard intravenous rituximab. Methods: In our two-stage, randomised, open-label, phase 3 trial, we enrolled patients with previously untreated grade 1-3a, CD20-positive follicular lymphoma at 67 centres in 23 countries. In stage 1, we randomly allocated patients 1:1 with the Pocock and Simon algorithm to intravenous rituximab (375 mg/m2) or fixed-dose subcutaneous rituximab (1400 mg), stratified by induction chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone or cyclophosphamide, vincristine, prednisone), Follicular Lymphoma International Prognostic Index score, and region. After randomisation, patients received one induction dose of intravenous rituximab in cycle 1 and then allocated treatment for cycles 2-8. Patients with a complete or partial response following induction therapy continued intravenous or subcutaneous rituximab as maintenance every 8 weeks. The primary endpoint was the ratio of observed rituximab serum trough concentrations (Ctrough) between groups at cycle 7 (before cycle 8 dosing) of induction treatment in a per-protocol population. Patients were analysed as treated for safety endpoints. Stage 2 follow-up is ongoing and is fully accrued. This study is registered with ClinicalTrials.gov, number NCT01200758. Findings: Between Feb 4, 2010, and Oct 21, 2011, we enrolled 127 patients. Pharmacokinetic data were available for 48 (75%) of 64 patients randomly allocated intravenous rituximab and 54 (86%) of 63 patients randomly allocated subcutaneous rituximab. Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab. 57 (88%) of 65 patients in the intravenous rituximab safety population had adverse events (30 [46%] grade ≥3), as did 57 (92%) of 62 patients in the subcutaneous rituximab safety population (29 [47%] grade ≥3). The most common grade 3 or worse adverse event in both groups was neutropenia (14 [22%] patients in the intravenous group and 16 [26%] patients in the subcutaneous group). Adverse events related to administration were mostly grade 1-2 and occurred in 21 (32%) patients in the intravenous group and 31 (50%) patients in the subcutaneous group. Interpretation: Stage 1 data show that the pharmacokinetic profile of subcutaneous rituximab was non-inferior to intravenous rituximab and was not associated with new safety concerns. Stage 2 will provide data for efficacy and safety of the subcutaneous administration. Funding: F Hoffmann-La Roche.

AB - Background: Intravenous rituximab is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent rituximab serum concentrations might improve convenience and save health-care resources without sacrificing clinical activity. We aimed to assess pharmacokinetic non-inferiority of 3 week cycles of fixed-dose subcutaneous rituximab versus standard intravenous rituximab. Methods: In our two-stage, randomised, open-label, phase 3 trial, we enrolled patients with previously untreated grade 1-3a, CD20-positive follicular lymphoma at 67 centres in 23 countries. In stage 1, we randomly allocated patients 1:1 with the Pocock and Simon algorithm to intravenous rituximab (375 mg/m2) or fixed-dose subcutaneous rituximab (1400 mg), stratified by induction chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone or cyclophosphamide, vincristine, prednisone), Follicular Lymphoma International Prognostic Index score, and region. After randomisation, patients received one induction dose of intravenous rituximab in cycle 1 and then allocated treatment for cycles 2-8. Patients with a complete or partial response following induction therapy continued intravenous or subcutaneous rituximab as maintenance every 8 weeks. The primary endpoint was the ratio of observed rituximab serum trough concentrations (Ctrough) between groups at cycle 7 (before cycle 8 dosing) of induction treatment in a per-protocol population. Patients were analysed as treated for safety endpoints. Stage 2 follow-up is ongoing and is fully accrued. This study is registered with ClinicalTrials.gov, number NCT01200758. Findings: Between Feb 4, 2010, and Oct 21, 2011, we enrolled 127 patients. Pharmacokinetic data were available for 48 (75%) of 64 patients randomly allocated intravenous rituximab and 54 (86%) of 63 patients randomly allocated subcutaneous rituximab. Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab. 57 (88%) of 65 patients in the intravenous rituximab safety population had adverse events (30 [46%] grade ≥3), as did 57 (92%) of 62 patients in the subcutaneous rituximab safety population (29 [47%] grade ≥3). The most common grade 3 or worse adverse event in both groups was neutropenia (14 [22%] patients in the intravenous group and 16 [26%] patients in the subcutaneous group). Adverse events related to administration were mostly grade 1-2 and occurred in 21 (32%) patients in the intravenous group and 31 (50%) patients in the subcutaneous group. Interpretation: Stage 1 data show that the pharmacokinetic profile of subcutaneous rituximab was non-inferior to intravenous rituximab and was not associated with new safety concerns. Stage 2 will provide data for efficacy and safety of the subcutaneous administration. Funding: F Hoffmann-La Roche.

UR - http://www.scopus.com/inward/record.url?scp=84896723699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896723699&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)70005-1

DO - 10.1016/S1470-2045(14)70005-1

M3 - Article

C2 - 24521993

AN - SCOPUS:84896723699

VL - 15

SP - 343

EP - 352

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 3

ER -